Effectiveness of Aspirin Plus Dipyridamole Versus Clopidogrel in Preventing Recurrent Ischemic Stroke: A Systematic Review.

IF 1.3 Q3 MEDICINE, GENERAL & INTERNAL
Cureus Pub Date : 2025-10-03 eCollection Date: 2025-10-01 DOI:10.7759/cureus.93790
Agbonmwanre E Osayagbon, Aliyu O Olaniyi, Japheth Oyovwi, Anup Banerjee, Olabisi P Lawal, Muhammad A Butt
{"title":"Effectiveness of Aspirin Plus Dipyridamole Versus Clopidogrel in Preventing Recurrent Ischemic Stroke: A Systematic Review.","authors":"Agbonmwanre E Osayagbon, Aliyu O Olaniyi, Japheth Oyovwi, Anup Banerjee, Olabisi P Lawal, Muhammad A Butt","doi":"10.7759/cureus.93790","DOIUrl":null,"url":null,"abstract":"<p><p>This systematic review evaluated the comparative effectiveness of aspirin plus extended-release dipyridamole (Asp+Dp) versus clopidogrel in preventing recurrent ischemic stroke. Three eligible studies were included, enrolling a total of 21,752 participants with a cumulative follow-up of 32 months. Many participants were recruited from the large-scale PROFESS trial (20,332 participants). Intervention dosing consisted of aspirin 25 mg combined with extended-release dipyridamole 200 mg administered twice daily, while the comparator was clopidogrel 75 mg once daily. In the PROFESS trial, recurrent stroke occurred in 916 patients (9.0%) in the Asp+Dp group and 898 patients (8.8%) in the clopidogrel group. The combined risk of recurrent stroke or major haemorrhagic events was comparable between groups, affecting 1,194 participants (11.7%) receiving Asp+Dp and 1,156 participants (11.4%) receiving clopidogrel. With respect to antiplatelet activity, one randomised pilot study demonstrated that Asp+Dp was associated with a delayed but significant reduction in the expression of several activation-dependent platelet receptors. Conversely, clopidogrel monotherapy was associated with earlier and more potent antiplatelet activity. Clinically, these study findings suggest that clopidogrel exerts more potent and earlier antiplatelet effects, whereas Asp+Dp produces broader but delayed downregulation of multiple platelet activation pathways. Regarding functional outcome recurrence, mortality, bleeding risk, or serious adverse events in patients with acute, mild ischemic stroke, no significant differences were observed between Asp+Dp and clopidogrel, with both regimens being practical and feasible for clinical use. In conclusion, while both therapies demonstrate comparable clinical effectiveness, further research is warranted to evaluate their long-term impact on quality of life in patients with ischemic stroke.</p>","PeriodicalId":93960,"journal":{"name":"Cureus","volume":"17 10","pages":"e93790"},"PeriodicalIF":1.3000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494369/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cureus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7759/cureus.93790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

This systematic review evaluated the comparative effectiveness of aspirin plus extended-release dipyridamole (Asp+Dp) versus clopidogrel in preventing recurrent ischemic stroke. Three eligible studies were included, enrolling a total of 21,752 participants with a cumulative follow-up of 32 months. Many participants were recruited from the large-scale PROFESS trial (20,332 participants). Intervention dosing consisted of aspirin 25 mg combined with extended-release dipyridamole 200 mg administered twice daily, while the comparator was clopidogrel 75 mg once daily. In the PROFESS trial, recurrent stroke occurred in 916 patients (9.0%) in the Asp+Dp group and 898 patients (8.8%) in the clopidogrel group. The combined risk of recurrent stroke or major haemorrhagic events was comparable between groups, affecting 1,194 participants (11.7%) receiving Asp+Dp and 1,156 participants (11.4%) receiving clopidogrel. With respect to antiplatelet activity, one randomised pilot study demonstrated that Asp+Dp was associated with a delayed but significant reduction in the expression of several activation-dependent platelet receptors. Conversely, clopidogrel monotherapy was associated with earlier and more potent antiplatelet activity. Clinically, these study findings suggest that clopidogrel exerts more potent and earlier antiplatelet effects, whereas Asp+Dp produces broader but delayed downregulation of multiple platelet activation pathways. Regarding functional outcome recurrence, mortality, bleeding risk, or serious adverse events in patients with acute, mild ischemic stroke, no significant differences were observed between Asp+Dp and clopidogrel, with both regimens being practical and feasible for clinical use. In conclusion, while both therapies demonstrate comparable clinical effectiveness, further research is warranted to evaluate their long-term impact on quality of life in patients with ischemic stroke.

Abstract Image

阿司匹林联合双嘧达莫与氯吡格雷预防缺血性卒中复发的有效性:一项系统评价。
本系统评价了阿司匹林加缓释双嘧达莫(Asp+Dp)与氯吡格雷在预防缺血性卒中复发中的比较效果。纳入三项符合条件的研究,共纳入21752名参与者,累计随访32个月。许多参与者是从大规模的PROFESS试验(20,332名参与者)中招募的。干预剂量为阿司匹林25 mg联合缓释双嘧达莫200 mg,每日2次,而比较剂为氯吡格雷75 mg,每日1次。在PROFESS试验中,Asp+Dp组有916例(9.0%)患者发生卒中复发,氯吡格雷组有898例(8.8%)患者发生卒中复发。卒中复发或主要出血事件的综合风险在两组之间具有可比性,分别有1194例(11.7%)接受Asp+Dp治疗和1156例(11.4%)接受氯吡格雷治疗。关于抗血小板活性,一项随机试点研究表明,Asp+Dp与几种活化依赖性血小板受体表达的延迟但显著降低有关。相反,氯吡格雷单药治疗与更早和更有效的抗血小板活性相关。临床上,这些研究结果表明氯吡格雷发挥更有效和更早的抗血小板作用,而Asp+Dp对多种血小板激活途径产生更广泛但延迟的下调。在急性、轻度缺血性脑卒中患者的功能结局复发、死亡率、出血风险或严重不良事件方面,Asp+Dp与氯吡格雷无显著差异,两种方案均具有临床应用的实用性和可行性。总之,虽然两种治疗方法的临床疗效相当,但仍需要进一步的研究来评估它们对缺血性卒中患者生活质量的长期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信